Annual CFO
-$287.78 M
-$204.26 M-244.55%
December 31, 2023
Summary
- As of February 7, 2025, RXRX annual cash flow from operations is -$287.78 million, with the most recent change of -$204.26 million (-244.55%) on December 31, 2023.
- During the last 3 years, RXRX annual CFO has fallen by -$242.38 million (-533.89%).
- RXRX annual CFO is now -533.89% below its all-time high of -$45.40 million, reached on December 31, 2020.
Performance
RXRX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$59.23 M
+$22.99 M+27.97%
September 30, 2024
Summary
- As of February 7, 2025, RXRX quarterly cash flow from operations is -$59.23 million, with the most recent change of +$22.99 million (+27.97%) on September 30, 2024.
- Over the past year, RXRX quarterly CFO has increased by +$43.08 million (+42.11%).
- RXRX quarterly CFO is now -176.53% below its all-time high of $77.39 million, reached on March 31, 2022.
Performance
RXRX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$317.82 M
+$13.70 M+4.13%
September 30, 2024
Summary
- As of February 7, 2025, RXRX TTM cash flow from operations is -$317.82 million, with the most recent change of +$13.70 million (+4.13%) on September 30, 2024.
- Over the past year, RXRX TTM CFO has dropped by -$1.06 million (-0.33%).
- RXRX TTM CFO is now -1683.81% below its all-time high of -$17.82 million, reached on March 31, 2020.
Performance
RXRX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
RXRX Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -244.6% | +42.1% | -0.3% |
| 3 y3 years | -533.9% | -32.4% | -280.5% |
| 5 y5 years | -404.5% | -32.4% | -280.5% |
RXRX Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -244.6% | at low | -176.5% | +42.1% | -529.7% | +4.1% |
| 5 y | 5-year | -533.9% | at low | -176.5% | +42.1% | -1683.8% | +4.1% |
| alltime | all time | -533.9% | at low | -176.5% | +42.1% | -1683.8% | +4.1% |
Recursion Pharmaceuticals Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$59.23 M(-28.0%) | -$317.82 M(-4.1%) |
| Jun 2024 | - | -$82.22 M(-19.6%) | -$331.52 M(+4.7%) |
| Mar 2024 | - | -$102.30 M(+38.1%) | -$316.76 M(+10.1%) |
| Dec 2023 | -$287.78 M(+244.5%) | -$74.08 M(+1.6%) | -$287.78 M(+11.3%) |
| Sep 2023 | - | -$72.92 M(+8.1%) | -$258.45 M(+7.7%) |
| Jun 2023 | - | -$67.47 M(-8.0%) | -$240.07 M(+2.5%) |
| Mar 2023 | - | -$73.32 M(+63.8%) | -$234.23 M(+180.4%) |
| Dec 2022 | -$83.52 M | -$44.75 M(-18.0%) | -$83.52 M(-16.4%) |
| Sep 2022 | - | -$54.54 M(-11.5%) | -$99.93 M(+27.4%) |
| Jun 2022 | - | -$61.62 M(-179.6%) | -$78.44 M(+55.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | $77.39 M(-226.5%) | -$50.47 M(-68.2%) |
| Dec 2021 | -$158.61 M(+249.4%) | -$61.16 M(+85.1%) | -$158.61 M(+78.5%) |
| Sep 2021 | - | -$33.05 M(-1.8%) | -$88.88 M(+18.1%) |
| Jun 2021 | - | -$33.65 M(+9.4%) | -$75.29 M(+29.1%) |
| Mar 2021 | - | -$30.75 M(-458.7%) | -$58.34 M(+28.5%) |
| Dec 2020 | -$45.40 M(-20.4%) | - | - |
| Dec 2020 | - | $8.57 M(-144.1%) | -$45.40 M(-15.9%) |
| Sep 2020 | - | -$19.46 M(+16.5%) | -$53.97 M(+56.4%) |
| Jun 2020 | - | -$16.70 M(-6.3%) | -$34.52 M(+93.7%) |
| Mar 2020 | - | -$17.82 M | -$17.82 M |
| Dec 2019 | -$57.04 M | - | - |
FAQ
- What is Recursion Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals annual CFO year-on-year change?
- What is Recursion Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals quarterly CFO year-on-year change?
- What is Recursion Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals TTM CFO year-on-year change?
What is Recursion Pharmaceuticals annual cash flow from operations?
The current annual CFO of RXRX is -$287.78 M
What is the all time high annual CFO for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high annual cash flow from operations is -$45.40 M
What is Recursion Pharmaceuticals annual CFO year-on-year change?
Over the past year, RXRX annual cash flow from operations has changed by -$204.26 M (-244.55%)
What is Recursion Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of RXRX is -$59.23 M
What is the all time high quarterly CFO for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high quarterly cash flow from operations is $77.39 M
What is Recursion Pharmaceuticals quarterly CFO year-on-year change?
Over the past year, RXRX quarterly cash flow from operations has changed by +$43.08 M (+42.11%)
What is Recursion Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of RXRX is -$317.82 M
What is the all time high TTM CFO for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high TTM cash flow from operations is -$17.82 M
What is Recursion Pharmaceuticals TTM CFO year-on-year change?
Over the past year, RXRX TTM cash flow from operations has changed by -$1.06 M (-0.33%)